Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of hirudin for detecting blood clotting tetrachoric aspects after inactivation under specific conditions

A specific condition, hirudin technology, applied in the field of medical devices, can solve the problem that hirudin cannot be used to detect blood coagulation, block thrombin hemostasis reaction, etc., to delay the disease, solve misdiagnosis, and reduce the effect of proportion problems.

Active Publication Date: 2013-09-11
天津百新生物技术研发有限公司
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0015] In addition, due to the unique anticoagulant principle of hirudin, its specific combination with thrombin can inhibit the coagulation of fibrinogen and block the hemostatic reaction catalyzed by thrombin.
Based on the above problems, hirudin cannot be used to detect the four coagulation items, and the detected data after adding a separate hirudin anticoagulant to the blood are all 0

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of hirudin for detecting blood clotting tetrachoric aspects after inactivation under specific conditions
  • Application of hirudin for detecting blood clotting tetrachoric aspects after inactivation under specific conditions
  • Application of hirudin for detecting blood clotting tetrachoric aspects after inactivation under specific conditions

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0043] The experimenter was a 35-year-old healthy male. 2. This test is a comparison of the experimental data of the four coagulation items measured after using hirudin alone as an anticoagulant and hirudin + inactivating agent. This data can verify the problem of using hirudin alone as an anticoagulant and compare the experimental data obtained by using hirudin+inactivator.

[0044] The four coagulation values ​​measured by hirudin without adding inactivating agent

[0045] English name Chinese name result Reference range unit PT prothrombin time 106 70-120 % PT-INR PT-INR 0 0.8-1.5 PT-sec plasma prothrombin time 0 11-14.5 sec APTT activated partial thromboplastin time 0 28-44 sec FIB plasma fibrinogen 0 2-4 g / l TT plasma thrombin time 0 14-21 sec

[0046] (2) Adding hirudin inactivator papain to determine the four coagulation values

[0047] English name Chinese name ...

Embodiment 2

[0054] The experimenter was a 35-year-old healthy female. (1) Values ​​determined using conventional doses of sodium citrate. (2), (3), (4) The comparative experimental data of using hirudin + three inactivators and (1):

[0055] (1) Four coagulation values ​​determined by normal use of sodium citrate as an anticoagulant

[0056] English name Chinese name result Reference range unit PT prothrombin time 106 70-120 % PT-INR PT-INR 1.1 0.8-1.5 PT-sec plasma prothrombin time 12.7 11-14.5 sec APTT activated partial thromboplastin time 38.6 28-44 sec FIB plasma fibrinogen 3.26 2-4 g / l TT plasma thrombin time 17.5 14-21 sec

[0057] (2) Four coagulation values ​​determined by adding hirudin inactivator papain

[0058] English name Chinese name result Reference range unit PT prothrombin time 106 70-120 % PT-INR PT-INR 1.1 0.8-1.5 PT-sec plasma p...

Embodiment 3

[0064] The experimenter was a 56-year-old male who had been diagnosed with cerebral thrombosis. (1) The value measured using a conventional dose of sodium citrate was inaccurate and could easily lead to misdiagnosis. (2) After the inspector determined the Hct value, he revised it The correct value determined after the addition of sodium citrate (3) The four values ​​of blood coagulation determined by the addition of hirudin inactivator papain (4) The four values ​​of blood coagulation determined by the addition of hirudin inactivator enzyme protease (5) Leech The four values ​​of blood coagulation determined by adding the inactivator subtilisin:

[0065] (1) Values ​​determined by conventional doses of sodium citrate

[0066] English name Chinese name result Reference range unit PT prothrombin time 106 70-120 % PT-INR PT-INR 1.0 0.8-1.5 PT-sec plasma prothrombin time 12.0 11-14.5 sec APTT activated partial thrombopla...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of hirudin for detecting blood clotting tetrachoric aspects after inactivation under specific conditions. An inactivator for preparing inactivated hirudin is mainly papain or subtilisin or enzyme protease, wherein the weight fraction ratio of the hirudin to the papain is (1:1)-(1:5), the weight fraction ratio of the hirudin to the subtilisin is (1:1)-(1:5), andthe weight fraction ratio of the hirudin to the enzyme protease is (1:1)-(1:5). In the invention, the inactivated hirudin is adopted for the first time to detect blood clotting tetrachoric aspects, thereby solving the problem that the blood clotting tetrachoric aspects can not be detected by only using the hirudin. The invention can avoid the conditions of misdiagnosis, delay of the state of an illness, influence on treatment and the like because of improper prothrombin time (PT) caused by improperly adding the traditional anticoagulant sodium citrate.

Description

technical field [0001] The invention belongs to the technical field of medical devices, and in particular relates to the application of four aspects of blood coagulation detection after hirudin is inactivated under specific conditions. Background technique [0002] The 2010 edition of the "Chinese Pharmacopoeia" of the People's Republic of China, the first part records "HIRUDO". The second season is caught, scalded to death with boiling water, and dried in the sun or with low humidity. Processing: Wash the leech, cut into sections, and dry. Scalding leeches: Take clean leech segments and pour them with talc powder until they swell slightly according to the scalding method. Functions and indications: breaking blood, expelling blood stasis, promoting menstrual flow. For blood stasis amenorrhea, injury from falling. [0003] Foreign Medical Blood Transfusion and Blood Volume, Volume 16, Issue 6, 1993, records the Institute of Hematology, Chinese Academy of Medical Sciences,...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): G01N33/86
Inventor 刘晨刘金雪
Owner 天津百新生物技术研发有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com